Please assess the completion status of the following clinical trial:

Trial Title: Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Have voluntarily signed the informed consent form.~2. 18 years of age or older.~3. Chronic HCV infection as defined by anti-HCV antibody or HCV RNA detection for greater than 6 months.~4. HCV RNA plasma ≥ 10,000 IU/ml at screening.~5. HCV genotype 1-6.~6. HCV treatment naïve (no prior treatment with an approved or investigation anti-HCV medication).~7. Stage F0-3, based on: hepatic elastography \<12.5 kPa on Fibroscan® or APRI \<1.0.~8. If co-infection with HIV is documented, the subject must meet the following criteria:~   * ART naïve with CD4 T cell count \>500 cells/mm3; OR~  * On a stable ART regimen (containing only permissible ART - see protocol section 3.2) for \>8 weeks prior to screening visit, with CD4 T cell count \>200 cells/mm3 and a plasma HIV RNA level below the limit of detection.~9. Negative pregnancy test at screening and baseline (females of childbearing potential only).~10. All fertile females must be using effective contraception during treatment and during the 30 days after treatment end.~Exclusion Criteria:~1. History of any of the following:~   1. Clinically significant illness (other than HCV) or any other major medical disorder that may interfere with the participant treatment, assessment or compliance with the protocol; participants currently under evaluation for a potentially clinically significant illness (other than HCV) are also excluded.~  2. Clinical hepatic decompensation (i.e. ascites, encephalopathy or variceal haemorrhage).~  3. Solid organ transplant.~  4. History of severe, life-threatening or other significant sensitivity to any excipients of the study drugs.~2. Any of the following lab parameters at screening:~   1. ALT \> 10 x ULN~  2. AST \> 10 x ULN~  3. Direct bilirubin \> ULN~  4. Platelets \< 90,000/μL (cells/mm3) if Fibroscan® \<12.5 kPa OR \< 150,000/μL (cells/mm3) if Fibroscan® is unavailable and patient is included with APRI \<1~  5. Creatinine clearance (CLcr) \< 50 mL/min~  6. Haemoglobin \< 12g/dL for males; \<11g/dL for females~  7. Albumin \< LLN~  8. INR \> 1.5 ULN unless subject has known haemophilia or is stable on an anticoagulant regimen affecting INR~3. Pregnant or breastfeeding female.~4. HBV infection (HBsAg positive).~5. Use of prohibited concomitant medications as described in protocol section 5.2.~6. Chronic use of systemically administered immunosuppressive agents (e.g. prednisone equivalent \> 10 mg/day for \>2 weeks).~7. Therapy with any anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) ≤6 months prior to the first dose of study drug.~8. Any investigational drug ≤6 weeks prior to the first dose of study drug.~9. Ongoing severe psychiatric disease as judged by the treating physician.~10. Positive result of a urine drug screen at the Screening Visit for opiates, barbiturates, amphetamines, cocaine, benzodiazepines, phencyclidine, propoxyphene, or alcohol, with the exception of a positive result (including methadone) associated with documented short-term use or chronic stable use of a prescribed medication in that class.~11. Injecting drug use within the previous six months.~12. Inability or unwillingness to provide informed consent or abide by the requirements of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard monitoring schedule (Type: OTHER): Participants will have on-treatment clinic visits at weeks 4 and 8. Participants have also phone contact-based visits at weeks 4 and 8 (1-2 days prior to scheduled clinic visits).
- Simplified monitoring schedule (Type: EXPERIMENTAL): Participants will have no on-treatment clinic visits at weeks 4 and 8. Participants have phone contact-based visits at weeks 4 and 8.

Based on this trial design, predict the completion outcome and termination type (if applicable).